VINORELBINA CAPECITABIME PACLITAXEL AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS PRETREATED WITH ADJUVANT ANTHRACYCLINES - VNBCAPTAX

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-005683-87-IT

Enrollment

Registered

2006-01-25

Start date

2006-02-22

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

METASTATIC BREAST CANCER MedDRA version: 6.1 Level: PT Classification code 10055113

Interventions

Trade Name: NAVELBINE 10MG/ML FL1ML Pharmaceutical Form: Solution for infusion INN or Proposed INN: Vinorelbine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: METASTATIC BREAST CANCER ONE LESION MEASURABLE FOR RECIST CRITERIA ADJUVANT ANTHRACYCLINES TREATMENT Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: PREVIOUS CHEMOTHERAPY FOR ADVANCED DISEASE PREVIOUS THERAPY WITH VINORELBINE OR TAXANES PREVIOUS SECONO AND THIRD LINE HORMONOTHERAPY FOR ADVANCED DISEASE

Design outcomes

Primary

Measure	Time frame
Main Objective: ACTIVITY;Secondary Objective: TOXICITY TIME TO PROGRESSION OVERALL SURVIVAL;Primary end point(s): RESPONSE RATE EVALUATED WITH RECST CRITERIA	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026